Allogene Therapeutics (ALLO) Operating Leases (2018 - 2026)
Allogene Therapeutics (ALLO) posted Operating Leases of $81.1 million for Q1 2026, down 2.64% sequentially from $83.3 million in Q4 2025, and down 8.85% YoY from $88.9 million in Q1 2025.
Allogene Therapeutics (ALLO) Operating Leases (2018 - 2026) Analysis & Trends
Allogene Therapeutics has reported Operating Leases for 9 years, with the latest figure at $81.1 million in Q1 2026.
- Quarterly Operating Leases fell 8.85% year-over-year to $81.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $81.1 million (down 8.85% YoY) and the FY2025 annual result came in at $83.3 million, down 8.27% from the prior year.
- Operating Leases fell to $81.1 million in Q1 2026 per ALLO's latest filing, from $83.3 million in the prior quarter.
- Over five years, Operating Leases peaked at $98.2 million in Q2 2022 and troughed at $69.0 million in Q1 2022.
- A 5-year average of $88.1 million and a median of $90.1 million in 2023 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2022 and 2025: Operating Leases jumped 91.83% in 2022, then decreased 15.89% in 2025.
- Over 5 years, Operating Leases stood at $95.1 million in 2022, then dropped by 0.0% to $95.1 million in 2023, then fell by 4.59% to $90.8 million in 2024, then fell by 8.27% to $83.3 million in 2025, then fell by 2.64% to $81.1 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $81.1 million, $83.3 million, and $77.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Allogene Therapeutics | 707.96 Mn | 707.96 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 79.01 Mn |
| Mar 31, 2026 | 81.05 Mn |
| Dec 31, 2025 | 83.25 Mn |
| Sep 30, 2025 | 77.13 Mn |
| Jun 30, 2025 | 79.24 Mn |
| Mar 31, 2025 | 88.92 Mn |
| Dec 31, 2024 | 90.76 Mn |
| Sep 30, 2024 | 85.14 Mn |
| Jun 30, 2024 | 94.21 Mn |
| Mar 31, 2024 | 88.92 Mn |
| Dec 31, 2023 | 95.12 Mn |
| Sep 30, 2023 | 90.10 Mn |
| Jun 30, 2023 | 91.82 Mn |
| Mar 31, 2023 | 93.51 Mn |
| Dec 31, 2022 | 95.12 Mn |
| Sep 30, 2022 | 96.71 Mn |
| Jun 30, 2022 | 98.23 Mn |
| Mar 31, 2022 | 69.04 Mn |
| Dec 31, 2021 | 69.93 Mn |
| Sep 30, 2021 | 50.64 Mn |